Search results
Theravance Biopharma (TBPH) to Sell Trelegy Royalty Interests
Zacks via Yahoo Finance· 2 years agoTheravance Biopharma (TBPH) agrees to sell its Trelegy royalty interests to Royalty Pharma. The...
GSK Gears Up for Q1 Earnings: Here's What to Expect
Zacks via Yahoo Finance· 1 month agoWe expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Nucala, Trelegy Ellipta and Shingrix to drive first-quarter sales performance.
GSK Gears Up for Q2 Earnings: Will It Surpass Estimates?
Zacks via Yahoo Finance· 10 months agoWe expect GSK plc. GSK to beat expectations when it reports second-quarter 2023 results on Jul 26....
Theravance Biopharma, Innoviva Gain On Selling TRELEGY ELLIPTA Royalty Interests
Benzinga via Yahoo Finance· 2 years agoTheravance Biopharma, Inc. (NASDAQ: TBPH) has agreed to sell all of its units in Theravance...
A Life-long Asthma Patient Shares How She’s Learned to Manage Her Condition
Parade via Yahoo News· 1 year agoRashelle Stocker was diagnosed with asthma in third grade after having her first attack on the...
GSK's Q3 Earnings Beat, Ups 2022 Sales Outlook, Stock Up
Zacks via Yahoo Finance· 2 years agoGSK plc GSK reported third-quarter 2022 adjusted earnings of $1.09 per American depositary share...
These Inhalers No Longer Cost More Than $35 Per Month
Verywell Health via Yahoo News· 2 months agoGrace Cary / Getty Images Fact checked by Nick Blackmer Key Takeaways Three major pharmaceutical...
See price hikes for top 25 drugs covered by Medicare; NJ drugmakers sue to stop change
App.com | Asbury Park Press via Yahoo Finance· 9 months agoAverage prices for 25 widely used drugs covered by Medicare more than tripled since they were...
GSK Gears Up to Report Q1 Earnings: What's in the Cards?
Zacks via Yahoo Finance· 1 year agoGSK plc. GSK will report first-quarter 2023 results on Apr 26, before the opening bell. In the last...
Glaxo (GSK) Up 3.1% Since Last Earnings Report: Can It Continue?
Zacks via Yahoo Finance· 3 months agoIt has been about a month since the last earnings report for GSK (GSK). Shares have added about 3.1%...